Answers are grounded in this paper and cite their sources.
[1] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115 24. [2] Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Negrier S, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Oral (abstract 5024). Presented at the 44th American Society of Clinical Oncology Annual meeting, Chicago, USA, May 30 June 3, 2008. [3] Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomized controlled trial. Lancet 2006;368:1329 38. [4] Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204 12. [5] Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332 44. [6] Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370 (9604):2011 19. [7] Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474 81. [8] Pfizer Inc. SUTENT, Summary of Product Characteristics. January 2008. Accessed 23/04/2008. http://emc.medicines. org.uk/emc/industry/default.asp?page displaydoc.aspd3:682 92. [11] Joensuu H. Cardiotoxicity of sunitinib. Lancet 2007;370: 1978 9.
No takes yet. Share an insight, caveat, or question.
Melichar et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: